{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:04:06Z","timestamp":1740107046271,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00520-022-07081-8","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T15:09:31Z","timestamp":1650985771000},"page":"6299-6305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Propensity score-matching analysis comparing safety outcomes of appetite-stimulating medications in oncology patients"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-0748","authenticated-orcid":false,"given":"Elizabeth","family":"Marie Gavioli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aia","family":"Gamaleldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nourhan","family":"Eladghm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etty","family":"Vider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"issue":"1","key":"7081_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/apm.2018.05.08","volume":"8","author":"DS Childs","year":"2019","unstructured":"Childs DS, Jatoi A (2019) A hunger for hunger: a review of palliative therapies for cancer-associated anorexia. Ann Palliat Med 8(1):50\u201358. https:\/\/doi.org\/10.21037\/apm.2018.05.08","journal-title":"Ann Palliat Med"},{"issue":"8","key":"7081_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/jcm8081211","volume":"8","author":"P Ravasco","year":"2019","unstructured":"Ravasco P (2019) Nutrition in cancer patients. J Clin Med 8(8):1211. https:\/\/doi.org\/10.3390\/jcm8081211","journal-title":"J Clin Med"},{"unstructured":"Megace\u00ae ES. Package insert. PAR Pharmaceutical Companies, Inc., Spring Valley, NY; September 2014. Accessed 20 Sept 2020 .https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021778s018lbl.pdf","key":"7081_CR3"},{"issue":"4","key":"7081_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/nano.2006.1.4.411","volume":"1","author":"SS Yeh","year":"2006","unstructured":"Yeh SS, Schuster MW (2006) Megestrol acetate in cachexia and anorexia. Int J Nanomedicine 1(4):411\u20136. https:\/\/doi.org\/10.2147\/nano.2006.1.4.411","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"7081_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.2002.20.2.567","volume":"20","author":"A Jatoi","year":"2002","unstructured":"Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20(2):567\u201373. https:\/\/doi.org\/10.1200\/JCO.2002.20.2.567","journal-title":"J Clin Oncol"},{"doi-asserted-by":"publisher","unstructured":"Ruiz Garcia V, L\u00f3pez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. (2013) Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013(3):CD004310.: https:\/\/doi.org\/10.1002\/14651858.CD004310.pub3","key":"7081_CR6","DOI":"10.1002\/14651858.CD004310.pub3"},{"issue":"7","key":"7081_CR7","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00520-018-4047-y","volume":"26","author":"B Kouchaki","year":"2018","unstructured":"Kouchaki B, Janbabai G, Alipour A, Ala S, Borhani S, Salehifar E (2018) Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. Support Care Cancer 26(7):2479\u20132489. https:\/\/doi.org\/10.1007\/s00520-018-4047-y","journal-title":"Support Care Cancer"},{"issue":"4","key":"7081_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/pbc.24828","volume":"61","author":"GD Cuvelier","year":"2014","unstructured":"Cuvelier GD, Baker TJ, Peddie EF et al (2014) A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and\/or cancer therapy. Pediatr Blood Cancer 61(4):672\u20139. https:\/\/doi.org\/10.1002\/pbc.24828","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"7081_CR9","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.7314\/apjcp.2014.15.23.10165","volume":"15","author":"C Ordu","year":"2014","unstructured":"Ordu C, Pilanci KN, Koksal UI et al (2014) Can megestrol acetate induce thrombosis in advanced oncology patients receiving chemotherapy? Asian Pac J Cancer Prev 15(23):10165\u20139. https:\/\/doi.org\/10.7314\/apjcp.2014.15.23.10165","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"7081_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","volume":"31","author":"C Madeddu","year":"2012","unstructured":"Madeddu C, Dess\u00ec M, Panzone F et al (2012) Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib \u00b1 megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome. Clin Nut 31(2):176\u201382. https:\/\/doi.org\/10.1016\/j.clnu.2011.10.005","journal-title":"Clin Nut"},{"issue":"4","key":"7081_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/030089160208800406","volume":"88","author":"HC Ulutin","year":"2002","unstructured":"Ulutin HC, Arpaci F, Pak Y (2002) Megestrol acetate for cachexia and anorexia in advanced non-small cell lung cancer: a randomized study comparing two different doses. Tumori 88(4):277\u2013280","journal-title":"Tumori"},{"issue":"5","key":"7081_CR12","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/s0360-3016(01)02782-1","volume":"52","author":"RP McQuellon","year":"2002","unstructured":"McQuellon RP, Moose DB, Russell GB et al (2002) Supportive use of megestrol acetate (Megace) with head\/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 52(5):1180\u20135. https:\/\/doi.org\/10.1016\/s0360-3016(01)02782-1","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"7081_CR13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.20452\/pamw.510","volume":"118","author":"W Le\u015bniak","year":"2008","unstructured":"Le\u015bniak W, Ba\u0142a M, Jaeschke R, Krzakowski M (2008) Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome\u2014a systematic review and meta-analysis. Pol Arch Med Wewn 118(11):636\u2013644","journal-title":"Pol Arch Med Wewn"},{"issue":"3","key":"7081_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SA Anttila","year":"2001","unstructured":"Anttila SA, Leinonen EV (2001) A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7(3):249\u201364. https:\/\/doi.org\/10.1111\/j.1527-3458.2001.tb00198.x","journal-title":"CNS Drug Rev"},{"unstructured":"Remeron. Package insert. Organon USA Inc., Roseland, NJ; July 2007. Accessed 27 Sept 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020415s019,021208s010lbl.pdf","key":"7081_CR15"},{"key":"7081_CR16","doi-asserted-by":"publisher","first-page":"893629","DOI":"10.1155\/2011\/893629","volume":"2011","author":"N Nihalani","year":"2011","unstructured":"Nihalani N, Schwartz TL, Siddiqui UA, Megna JL (2011) Weight gain, obesity, and psychotropic prescribing. J Obes 2011:893629. https:\/\/doi.org\/10.1155\/2011\/893629","journal-title":"J Obes"},{"issue":"2","key":"7081_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/1049909109345685","volume":"27","author":"RP Riechelmann","year":"2010","unstructured":"Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C (2010) Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care 27(2):106\u201310. https:\/\/doi.org\/10.1177\/1049909109345685","journal-title":"Am J Hosp Palliat Care"},{"issue":"11","key":"7081_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00520-008-0425-1","volume":"16","author":"ES Cankurtaran","year":"2008","unstructured":"Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Turhan L, Alkis N (2008) Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer 16(11):129\u201318. https:\/\/doi.org\/10.1007\/s00520-008-0425-1","journal-title":"Support Care Cancer"},{"issue":"3","key":"7081_CR19","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2011.05.002","volume":"42","author":"MP Davis","year":"2011","unstructured":"Davis MP, Kirkova J, Lagman R, Walsh D, Karafa M (2011) Intolerance to mirtazapine in advanced cancer. J Pain Symptom Manage 42(3):e4-7. https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.05.002","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"7081_CR20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/s0885-3924(02)00381-0","volume":"23","author":"DE Theobald","year":"2002","unstructured":"Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD (2002) An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 23(5):442\u20137. https:\/\/doi.org\/10.1016\/s0885-3924(02)00381-0","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"7081_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.amjopharm.2007.06.004","volume":"5","author":"D Bodenner","year":"2007","unstructured":"Bodenner D, Spencer T, Riggs AT, Redman C, Strunk B, Hughes T (2007) A retrospective study of the association between megestrol acetate administration and mortality among nursing home residents with clinically significant weight loss. Am J Geriatr Pharmacother 5(2):137\u201346. https:\/\/doi.org\/10.1016\/j.amjopharm.2007.06.004","journal-title":"Am J Geriatr Pharmacother"},{"issue":"4","key":"7081_CR22","doi-asserted-by":"publisher","first-page":"e0215289","DOI":"10.1371\/journal.pone.0215289","volume":"14","author":"B Kollhorst","year":"2019","unstructured":"Kollhorst B, Jobski K, Krappweis J, Schink T, Garbe E, Schmedt N (2019) Antidepressants and the risk of death in older patients with depression: a population-based cohort study. PLoS One 14(4):e0215289. https:\/\/doi.org\/10.1371\/journal.pone.0215289","journal-title":"PLoS One"},{"issue":"6","key":"7081_CR23","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1002\/ehf2.12861","volume":"7","author":"R Sweda","year":"2020","unstructured":"Sweda R, Siontis GCM, Nikolakopoulou A, Windecker S, Pilgrim T (2020) Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis. ESC Heart Fail 7(6):3610\u20133620. https:\/\/doi.org\/10.1002\/ehf2.12861","journal-title":"ESC Heart Fail"},{"issue":"10","key":"7081_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jamapsychiatry.2013.149","volume":"70","author":"A Khan","year":"2013","unstructured":"Khan A, Faucett J, Morrison S, Brown WA (2013) Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit\/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry 70(10):1091\u20131099. https:\/\/doi.org\/10.1001\/jamapsychiatry.2013.149","journal-title":"JAMA Psychiatry"},{"key":"7081_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jad.2020.01.021","volume":"266","author":"W Cai","year":"2020","unstructured":"Cai W, Mueller C, Shetty H, Perera G, Stewart R (2020) Predictors of mortality in people with late-life depression: a retrospective cohort study. J Affect Disord 266:695\u2013701. https:\/\/doi.org\/10.1016\/j.jad.2020.01.021","journal-title":"J Affect Disord"},{"issue":"1","key":"7081_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12916-018-1022-x","volume":"16","author":"C Coupland","year":"2018","unstructured":"Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J (2018) Antidepressant use and risk of adverse outcomes in people aged 20\u201364 years: cohort study using a primary care database. BMC Med 16(1):36. https:\/\/doi.org\/10.1186\/s12916-018-1022-x","journal-title":"BMC Med"},{"issue":"4","key":"7081_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bcp.12829","volume":"81","author":"B Danielsson","year":"2016","unstructured":"Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J (2016) Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol 81(4):773\u201383. https:\/\/doi.org\/10.1111\/bcp.12829","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"7081_CR28","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/AOG.0b013e31826af61a","volume":"120","author":"DA Grimes","year":"2012","unstructured":"Grimes DA, Schulz KF (2012) False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol 120(4):920\u20137. https:\/\/doi.org\/10.1097\/AOG.0b013e31826af61a","journal-title":"Obstet Gynecol"},{"issue":"1","key":"7081_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.9740\/mhc.2020.01.030","volume":"10","author":"ND Allen","year":"2020","unstructured":"Allen ND, Leung JG, Palmer BA (2020) Mirtazapine\u2019s effect on the QT interval in medically hospitalized patients. Ment Health Clin 10(1):30\u201333. https:\/\/doi.org\/10.9740\/mhc.2020.01.030","journal-title":"Ment Health Clin"},{"issue":"9","key":"7081_CR30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/pds.2181","volume":"20","author":"CE Leonard","year":"2011","unstructured":"Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S (2011) Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 20(9):903\u201313. https:\/\/doi.org\/10.1002\/pds.2181","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"7081_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00004714-199604000-00006","volume":"16","author":"JH Tulen","year":"1996","unstructured":"Tulen JH, Bruijn JA, de Man KJ, Pepplinkhuizen L, van den Meiracker AH, Man in \u2019t Veld AJ (1996) Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770). J Clin Psychopharmacol 16(2):135\u201345. https:\/\/doi.org\/10.1097\/00004714-199604000-00006","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"7081_CR32","first-page":"191","volume":"26","author":"WT Smith","year":"1990","unstructured":"Smith WT, Glaudin V, Panagides J, Gilvary E (1990) Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 26(2):191\u2013196","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"7081_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458\u2013464. https:\/\/doi.org\/10.1001\/archinte.166.4.458","journal-title":"Arch Intern Med"},{"issue":"9","key":"7081_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4251\/wjgo.v9.i9.363","volume":"9","author":"RL Metcalf","year":"2017","unstructured":"Metcalf RL, Al-Hadithi E, Hopley N et al (2017) Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers. World J Gastrointest Oncol 9(9):363\u2013371. https:\/\/doi.org\/10.4251\/wjgo.v9.i9.363","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"7081_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1060028018802816","volume":"53","author":"ML Howard","year":"2019","unstructured":"Howard ML, Hossaini R, Tolar C, Gaviola ML (2019) Efficacy and safety of appetite-stimulating medications in the inpatient setting. Ann Pharmacother 53(3):261\u2013267. https:\/\/doi.org\/10.1177\/1060028018802816","journal-title":"Ann Pharmacother"},{"issue":"6","key":"7081_CR36","first-page":"248","volume":"1","author":"JC Bolen","year":"2000","unstructured":"Bolen JC, Andersen RE, Bennett RG (2000) Deep vein thrombosis as a complication of megestrol acetate therapy among nursing home residents. J Am Med Dir Assoc 1(6):248\u2013252","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"7081_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.neo.7900263","volume":"4","author":"GJ Caine","year":"2002","unstructured":"Caine GJ, Stonelake PS, Lip GY, Kehoe ST (2002) The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 4(6):465\u201373. https:\/\/doi.org\/10.1038\/sj.neo.7900263","journal-title":"Neoplasia"},{"issue":"10","key":"7081_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","volume":"10","author":"NB AbdolRazak","year":"2018","unstructured":"AbdolRazak NB, Jones G, Bhandari M, Berndt MC, Metharom P (2018) Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 10(10):380. https:\/\/doi.org\/10.3390\/cancers10100380","journal-title":"Cancers (Basel)"},{"issue":"21","key":"7081_CR39","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/archinternmed.2009.357","volume":"169","author":"JC Woolcott","year":"2009","unstructured":"Woolcott JC, Richardson KJ, Wiens MO et al (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons [published correction appears in Arch Intern Med. 2010;170(5):477]. Arch Intern Med 169(21):1952\u20131960. https:\/\/doi.org\/10.1001\/archinternmed.2009.357","journal-title":"Arch Intern Med"},{"doi-asserted-by":"publisher","unstructured":"American Geriatrics Society (2019) updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc 67(4):674\u2013694. https:\/\/doi.org\/10.1111\/jgs.15767","key":"7081_CR40","DOI":"10.1111\/jgs.15767"},{"issue":"3","key":"7081_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0269881116681399","volume":"31","author":"J Karsten","year":"2017","unstructured":"Karsten J, Hagenauw LA, Kamphuis J, Lancel M (2017) Low doses of mirtazapine or quetiapine for transient insomnia: a randomised, double-blind, cross-over, placebo-controlled trial. J Psychopharmacol 31(3):327\u2013337. https:\/\/doi.org\/10.1177\/0269881116681399","journal-title":"J Psychopharmacol"},{"issue":"7819","key":"7081_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.d4551","volume":"343","author":"C Coupland","year":"2011","unstructured":"Coupland C, Dhiman P, Morriss R et al (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. Br Med J 343(7819):1\u201315. https:\/\/doi.org\/10.1136\/bmj.d4551","journal-title":"Br Med J"},{"issue":"8","key":"7081_CR43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00228-019-02668-3","volume":"75","author":"F Wedmann","year":"2019","unstructured":"Wedmann F, Himmel W, Nau R (2019) Medication and medical diagnosis as risk factors for falls in older hospitalized patients. Eur J Clin Pharmacol 75(8):1117\u20131124. https:\/\/doi.org\/10.1007\/s00228-019-02668-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"7081_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1053\/j.jrn.2015.11.002","volume":"26","author":"LD Wazny","year":"2016","unstructured":"Wazny LD, Nadurak S, Orsulak C, Giles-Smith L, Tangri N (2016) The efficacy and safety of megestrol acetate in protein-energy wasting due to chronic kidney disease: a systematic review. J Ren Nutr 26(3):168\u201376. https:\/\/doi.org\/10.1053\/j.jrn.2015.11.002","journal-title":"J Ren Nutr"},{"issue":"1","key":"7081_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.9740\/mhc.2019.01.041","volume":"9","author":"M Shuman","year":"2019","unstructured":"Shuman M, Chukwu A, Van Veldhuizen N, Miller SA (2019) Relationship between mirtazapine dose and incidence of adrenergic side effects: an exploratory analysis. Ment Health Clin 9(1):41\u201347. https:\/\/doi.org\/10.9740\/mhc.2019.01.041","journal-title":"Ment Health Clin"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07081-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:05:22Z","timestamp":1727049922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07081-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["7081"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07081-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"17 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review boards of Mount Sinai School of Medicine and New York University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable for this retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Elizabeth Marie Gavioli is an employee of Dompe, U.S., Inc. All other authors declare that they do not have a conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}